Associations between tumor response to pembrolizumab and immune-related adverse events in metastatic melanoma patients

被引：0
|
作者：
Geszti, F. [1 ]
Czirbesz, K. [1 ]
Kenessey, I. [1 ]
Liszkay, G. [1 ]
机构：
[1] Natl Inst Oncol, Budapest, Hungary
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
8516
引用
收藏
页码：AB24 / AB24
页数：1
相关论文
共 50 条
  • [1] ASSOCIATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND SURVIVAL OF PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA TREATED WITH PEMBROLIZUMAB
    Nakamura, Kazutaka
    Toshio, Takagi
    Nemoto, Yuki
    Ishiyama, Yudai
    Ishihara, Hiroki
    Tachibana, Hidekazu
    Fukuda, Hironori
    Shinmura, Hiroaki
    Hashimoto, Yasunobu
    Kondo, Tsunenori
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Ishida, Hideki
    Tanabe, Kazunari
    JOURNAL OF UROLOGY, 2022, 207 (05): : E28 - E28
  • [2] Immune-related adverse events: pembrolizumab ± influenza vaccine
    Reactions Weekly, 2020, 1795 (1) : 8 - 8
  • [3] Incidence of thyroid immune-related adverse events in melanoma patients treated with pembrolizumab in an expanded access program
    Jeroen, de Filette
    Yanina, Jansen
    Max, Schreuer
    Hendrik, Everaert
    Brigitte, Velkeniers
    Bart, Neyns
    Bert, Bravenboer
    ACTA CLINICA BELGICA, 2016, 71 : 19 - 19
  • [4] Impact of sex on immune-related adverse events in patients with melanoma
    Ottaviano, Margaret
    Mallardo, Domenico
    Vitale, Maria Grazia
    Vanella, Vito
    Fordellone, Mario
    Festino, Lucia
    Trojaniello, Claudia
    Sparano, Francesca
    Facchini, Bianca Arianna
    Cioli, Eleonora
    Isaja, Antonio
    Cavalcanti, Ernesta
    Capone, Mariaelena
    Madonna, Gabriele
    Paone, Miriam
    Chiodini, Paolo
    Caraco, Corrado
    Simeone, Ester
    Ascierto, Paolo Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma
    Cao, Yenong
    Afzal, Muhammad Zubair
    Shirai, Keisuke
    BMJ CASE REPORTS, 2021, 14 (08)
  • [6] Immune-related adverse events after a single dose of pembrolizumab
    Vos, Hanne
    Lambein, Kathleen
    Wildiers, Hans
    Punie, Kevin
    Smeets, Ann
    EUROPEAN JOURNAL OF CANCER, 2021, 148 : 92 - 94
  • [7] Correlation between immune-related adverse events and outcomes in nivolumab/ipilimumab combination therapy for metastatic melanoma
    Rauwerdink, Daan
    Frederick, Dennie T.
    Sharova, Tatyana
    Marie, Genevieve
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [8] Pembrolizumab-induced lichen planus in patients with metastatic melanoma: a report of two cases and prognostic implications of cutaneous immune-related adverse events
    Tirnanic, Tanja
    Tiodorovic, Danica
    Vidovic, Natasa
    Balic, Mirjana
    Petrov, Nenad
    Kandolf, Lidija
    Mijuskovic, Zeljko
    ACTA DERMATOVENEROLOGICA ALPINA PANNONICA ET ADRIATICA, 2023, 32 (03): : 119 - 122
  • [9] Cutaneous immune-related adverse events and photodamaged skin in patients with metastatic melanoma: could nicotinamide be useful?
    De Giorgi, Vincenzo
    Colombo, Jacopo
    Trane, Luciana
    Silvestri, Flavia
    Venturi, Federico
    Zuccaro, Biancamaria
    Doni, Laura
    Stanganelli, Ignazio
    Covarelli, Piero
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2022, 47 (08) : 1558 - 1560
  • [10] IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS WITH METASTATIC MELANOMA TREATED WITH TREMELIMUMAB (CP-675,206)
    Wallis, N.
    Bulanhagui, C. A.
    ElSawah, G.
    Pavlov, D.
    Gomez-Navarro, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 242 - 242
12345